You are here

Retinal Pigment Epithelium Safety Study For Patients In B4711001

Last updated on July 31, 2018

FOR MORE INFORMATION
Study Location
Moorfields Eye Hospital NHS Foundation Trust
London, , EC1V 2PD United Kingdom
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Age Related Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
60+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.

- Previous participation in Protocol B4711001 and received treatment with PF-05206388.

- Subjects who are willing and able to comply with scheduled visits, and study
procedures.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- there are no exclusion criteria

NCT03102138
Pfizer
Recruiting
Retinal Pigment Epithelium Safety Study For Patients In B4711001

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

mCRPC With DNA Damage Repair Deficiencies (DDR)
NCT03395197
Males
18+
Years
Multiple Sites
Age Related Macular Degeneration
NCT01691261
All Genders
60+
Years
London,
Age Related Macular Degeneration
NCT03102138
All Genders
60+
Years
London,
Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration
NCT01245387
All Genders
Retinal Pigment Epithelium Safety Study For Patients In B4711001
Long Term, Open-label, Safety Follow Up Study Following Transplantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe)) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
Not Provided
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Age Related Macular Degeneration
Not Provided
observation
subjects treated in B4711001 with PF-05206388 will be assessed
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
October 4, 2020
October 4, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  • Previous participation in Protocol B4711001 and received treatment with PF-05206388.
  • Subjects who are willing and able to comply with scheduled visits, and study procedures.

Exclusion Criteria:

  • there are no exclusion criteria
Sexes Eligible for Study: All
60 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
United Kingdom
 
 
NCT03102138
B4711005
2015-002267-42 ( EudraCT Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now